Pheochromocytoma and paraganglioma syndromes: going on 2010

English version České info

Pheochromocytomas and paragangliomas are chromaffin cell tumors that produce, store (e.g. in vesicles), metabolize (e.g. to yield metabolites such as normetanephrine or metanephrine), and secrete (release) catecholamines (e.g. norepinephrine and epinephrine, or dopamine). The metabolism of catecholamines is a more consistent process than that of catecholamine secretion. Pheochromocytomas are found in the adrenal gland; closely related tumors of extra-adrenal location are classified as paragangliomas. Most pheochromocytoma and paraganglioma tumors (PTTs) represent sporadic tumors but about 20–30% of these tumors are familial. Mutations in six genes to date have been identified to be responsible for familial PTTs:

the von Hippel-Lindau (VHL) gene leading to VHL syndrome;
the RET gene leading to multiple endocrine neoplasia type 2;
the neurofibromatosis type 1 (NF-1) gene associated with von Recklinghausen’s disease; and 4 and 5. mutations of genes encoding the B, C, and D subunits of mitochondrial succinatedehydrogenase (SDHB, SDHC, and SDHD) associated with familial PTTs. The presence of catecholamine excess reflects various clinical signs and symptoms associated with PTTs. Hypertension is the most common sign and may be sustained or paroxysmal. Numerous independent studies have now confirmed that measurements of fractionated metanephrines (i.e. normetanephrine and metanephrine measured separately) in urine or plasma provide superior diagnostic sensitivity over measurement of the parent catecholamines. Current localization of PTTs should be based on the use of anatomical as well as specific functional imaging studies to proof that a tumor is indeed pheochromocytoma or paraganglioma. Laparoscopic surgery is now the technique of first choice for resection adrenal and extraadrenal PTTs. All patients with PTTs should receive appropriate preoperative medical management to block the effects of released catecholamines (blocking the synthesis and the action of catecholamines). Currently, there is no curative treatment for malignant PTTs.

Key words:
pheochromocytoma, paraganglioma, catecholamines, metanephrines, neuroendocrine, familial, metaiodobenzylguanidine scintigraphy, postitron emission tomography.

Autoři: Karel Pacak ¹; Tamara Prodanov ¹; Graeme Eisenhofer ³; Karen Adams ¹; Vitaly Kantorovich ²
Působiště autorů: Reproductive Biology and Medicine Branch, The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), MD, USA ¹; Division of Endocrinology and Metabolism University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA ²; Departments of Medicine and Clinical Chemistry, University of Dresden, Dresden Germany ³
Vyšlo v časopise: Ces Urol 2010; 14(1): 5-15
Kategorie: Přehledový článek

Souhrn

the von Hippel-Lindau (VHL) gene leading to VHL syndrome;
the RET gene leading to multiple endocrine neoplasia type 2;
the neurofibromatosis type 1 (NF-1) gene associated with von Recklinghausen’s disease; and 4 and 5. mutations of genes encoding the B, C, and D subunits of mitochondrial succinatedehydrogenase (SDHB, SDHC, and SDHD) associated with familial PTTs. The presence of catecholamine excess reflects various clinical signs and symptoms associated with PTTs. Hypertension is the most common sign and may be sustained or paroxysmal. Numerous independent studies have now confirmed that measurements of fractionated metanephrines (i.e. normetanephrine and metanephrine measured separately) in urine or plasma provide superior diagnostic sensitivity over measurement of the parent catecholamines. Current localization of PTTs should be based on the use of anatomical as well as specific functional imaging studies to proof that a tumor is indeed pheochromocytoma or paraganglioma. Laparoscopic surgery is now the technique of first choice for resection adrenal and extraadrenal PTTs. All patients with PTTs should receive appropriate preoperative medical management to block the effects of released catecholamines (blocking the synthesis and the action of catecholamines). Currently, there is no curative treatment for malignant PTTs.

Key words:
pheochromocytoma, paraganglioma, catecholamines, metanephrines, neuroendocrine, familial, metaiodobenzylguanidine scintigraphy, postitron emission tomography.

Zdroje

1. Pacak K, Chrousos GP, Koch CA, Lenders JW, Eisenhofer G. Pheochromocytoma: progress in diagnosis, therapy, and genetics. In: Margioris A, Chrousos GP eds. Adrenal Disorders. 1 ed. Totowa: Humana Press 2001; 479–523.

2. Elder EE, Elder G, Larsson C. Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor. J Surg Oncol 2005; 89: 193–201.

3. Manger WM, Gifford RW. Pheochromocytoma. J Clin Hypertens 2002; 4: 62–72.

4. Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J Urol 1992; 147: 1–10.

5. O’Riordain DS, Young WF, Jr., Grant CS, Carney JA, van Heerden JA. Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J Surg 1996; 20: 916–921.

6. Remine W, Chong G, van Heerden J, Sheps S, Harrison EJ. Current management of pheochromocytoma. Ann Surg 1974; 179: 740–748.

7. Klingler HC, Klingler PJ, Martin JK, Jr., Smallridge RC, Smith SL, Hinder RA. Pheochromocytoma. Urology 2001; 57: 1025–1032.

8. Bravo E. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev 1994; 15: 356–368.

9. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, Giovagnetti M, Opocher G, Angeli A. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000; 85: 637–644.

10. Manger W, Gifford R. Clinical and Experimental Pheochromocytoma. Cambridge, Massachusetts: Blackwell Science 1996.

11. Streeten DH, Anderson GH Jr. Mechanisms of orthostatic hypotension and tachycardia in patients with pheochromocytoma. Am J Hypertens 1996; 9: 760–769

12. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005; 366: 665-675.

13. Bravo EL, Gifford RW Jr. Pheochromocytoma. Endocrinol Metab Clin North Am 1993; 22: 329–341.

14. Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 2003; 24: 539–553.

15. Ram CV, Fierro-Carrion GA. Pheochromocytoma. Semin Nephrol 1995; 15: 126–137.

16. Steen RE, Kapelrud H, Haug E, Frey H. In vivo and in vitro inhibition by ketoconazole of ACTH secretion from a human thymic carcinoid tumour. Acta Endocrinol (Copenh) 1991; 125: 331–334.

17. Bouloux PG, Fakeeh M. Investigation of phaeochromocytoma. Clin Endocrinol (Oxf) 1995; 43: 657–664.

18. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M, Szmigielski C. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002; 346: 1459–1466.

19. Timmers H, Gimenez-Roqueplo AP, Mannelli M, Pacak K. Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer 2009; 16: 391–400.

20. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS, Eisenhofer G. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002; 287: 1427–1434.

21. Eisenhofer G, Siegert G, Kotzerke J, Bornstein SR, Pacak K. Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas. Horm Metab Res 2008; 40: 329–337.

22. Eisenhofer G, Goldstein DS, Sullivan P, Csako G, Brouwers FM, Lai EW, Adams KT, Pacak K. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma ethoxytyramine. J Clin Endocrinol Metab 2005; 90: 2086–2075.

23. Ilias I, Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheohcromocytoma. J Clin Endocrinol Metab 2004; 89: 479–491.

24. Mamede M, Carrasquillo JA, Chen CC, Del Corral P, Whatley M, Ilias I, Ayala A, Pacak K. Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamineand [123I]- metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. Nucl Med Commun 2006; 27: 31–36.

25. Timmers HJ, Eisenhofer G, Carrasquillo JA, Chen CC, Whatley M, Ling A, Adams KT, Pacak K. Use of 6-[18F]-fluorodopamine positron emission tomography as first-line investigation for the diagnosis and localization of non-metastatic and metastatic pheochromocytoma. Clin Endocrinol (Oxf) 2009; 71: 11–17.

26. Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab 2007; 92: 4069–4079.

27. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, Kimura N, Mannelli M, McNicol AM, Tischler AS. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metab 2007; 3: 92–102.

28. Goldstein RE, O’Neill JA, Jr., Holcomb GW, 3rd, Morgan WM, 3rd, Neblett WW, 3rd, Oates JA, Brown N, Nadeau J, Smith B, Page DL, Abumrad NN, Scott HW Jr. Clinical experience over 48 years with pheochromocytoma. Ann Surg 1999; 229: 755–764.

29. John H, Ziegler WH, Hauri D, Jaeger P. Pheochromocytomas: can malignant potential be predicted? Urology 1999; 53: 679–683.

30. Proye CA, Vix M, Jansson S, Tisell LE, Dralle H, Hiller W. “The” pheochromocytoma: a benign, intra-adrenal, hypertensive, sporadic unilateral tumor. Does it exist? World J Surg 1994; 18: 467–472.

31. Yu J, Pacak K Metastatic pheochromocytoma. Endocrinologist 2002; 12: 291–299.

32. Mundschenk J, Lehnert H. Malignant pheochromocytoma. Exp Clin Endocrinol Diabetes 1998; 106: 373–376.

33. Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 1988; 109: 267–273.

34. Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM, Pacak K, Fojo T. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 2008; 113: 2020–2028.